Magnetic Group Signaling (MGS®) Technology

Magnetic Group Signaling (MGS®) standardizes NMR systems and sample processing to ensure reproducible results on different NMR instruments.

Learn more

Nephrology. |Renal Function Assessment.

Development of chronic kidney disease (CKD) is a common consequence of many medical conditions, and its prevalence is rising. Predominant causes of CKD are hypertension and diabetes mellitus. Determination of Glomerular Filtration Rate (GFR) is one of the most common tests employed and a part of all standard blood panels. GFR is used to assess kidney functioning. GFR is consequently the most important marker for impaired renal function.

Currently, GFR determination is based on an estimation using clinical data and blood based biomarkers such as creatinine. GFR can either be measured (mGFR) by tracer based methods or estimated (eGFR) using clinical data and blood based biomarkers such as creatinine or cystatin C. However, mGFR methods are highly elaborate and time-consuming and eGFR lacks accuracy in a variety of common clinical situations. As a consequence clinical decision making is difficult especially early when intervention may retard progression to end-stage renal disease.


1. 2011–2014 National Health and Nutrition Examination Survey and the CKD Epidemiology Collaboration (CKD-EPI) equation.

GFR Estimation. |With the <i>AXINON<sup>&reg;</sup></i> System.

Advanced. Automated. Affordable.

Numares developed a novel multi-parametric serum test to significantly improve serum creatinine-based glomerular filtration rate estimation to allow for a more accurate and easy assessment of renal (kidney) function.

This would improve the treatment of patients with (chronic) renal diseases and monitoring of therapies with nephrotoxic drugs.

More information on the AXINON® System:
Go to FAQs

Technology. |The <i>AXINON<sup>&reg;</sup> System</i>.

Easy. Fast. Efficient.

The test will be available for the AXINON® System, which produces high-quality, standardized NMR spectra based on Numares’ Magnetic Group Signaling (MGS®) technology, which enables a throughput of more than 200 samples per day.

The combination of MGS® with the AXINON® System allows for spectral analysis with highly-reproducible results. The system is easy to use requiring minimal operator interaction. It is fast and efficient with automation capabilities allowing short hands-on-time and high walk-away capability.

To date, more than 2 million tests have been performed worldwide using Numares’ technology.

Go to Technology

* For Research Use only in the United States. Numares’ products are not yet available for sale within the United States; they have not yet been approved or cleared by the U.S. Food and Drug Administration.

You did not activate the necessary cookies for this content.

activate necessary cookies and show content